Shattuck Labs, Inc. (NASDAQ:STTK) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts have an average recommendation of "Moderate Buy" on Shattuck Labs from nine firms (seven buys, one hold, one sell) with a mean 1-year target of $12.50, and recent initiations/upgrades include Piper Sandler (overweight, $15 PT), Wedbush (raised target to $8) and other buy reissues.
• Shares trade around $7.72 with a 52-week range of $0.71–$8.33 and a market cap of $583M; the company reported -$0.12 EPS last quarter (matching consensus) and a revenue shortfall, and sell-side analysts project about -0.5 EPS for the current year.
• Shattuck Labs is a clinical-stage biotech developing immunotherapeutic vaccines to prevent and treat substance use disorders—principally targeting fentanyl—and institutional investors own roughly 58.7% of the stock while several hedge funds have recently added positions.

Shares of Shattuck Labs, Inc. (NASDAQ:STTK - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nine ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $12.50.

A number of equities analysts recently commented on the stock. Piper Sandler initiated coverage on shares of Shattuck Labs in a research report on Wednesday, January 28th. They set an "overweight" rating and a $15.00 price target on the stock. TD Cowen reissued a "buy" rating on shares of Shattuck Labs in a report on Friday, March 6th. Cantor Fitzgerald initiated coverage on shares of Shattuck Labs in a report on Monday. They issued an "overweight" rating on the stock. Wedbush raised their target price on shares of Shattuck Labs from $4.00 to $8.00 and gave the company an "outperform" rating in a report on Friday, March 6th. Finally, Wall Street Zen raised shares of Shattuck Labs from a "hold" rating to a "buy" rating in a report on Saturday, March 28th.

Hedge Funds Weigh In On Shattuck Labs

Hedge funds have recently bought and sold shares of the company. Turtle Creek Wealth Advisors LLC bought a new position in Shattuck Labs in the 3rd quarter valued at about $29,000. Virtu Financial LLC bought a new position in Shattuck Labs in the 3rd quarter valued at about $38,000. AQR Capital Management LLC increased its holdings in Shattuck Labs by 265.4% in the 1st quarter. AQR Capital Management LLC now owns 43,169 shares of the company's stock valued at $41,000 after buying an additional 31,355 shares during the period. Qube Research & Technologies Ltd bought a new position in Shattuck Labs in the 2nd quarter valued at about $44,000. Finally, Squarepoint Ops LLC bought a new position in Shattuck Labs in the 3rd quarter valued at about $46,000. 58.74% of the stock is owned by institutional investors.

Shattuck Labs Stock Performance

NASDAQ:STTK opened at $7.72 on Tuesday. Shattuck Labs has a 52 week low of $0.71 and a 52 week high of $8.33. The firm has a market cap of $583.48 million, a price-to-earnings ratio of -10.03 and a beta of 1.28. The firm's 50-day simple moving average is $6.01 and its 200 day simple moving average is $4.08.

Shattuck Labs (NASDAQ:STTK - Get Free Report) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.12) EPS for the quarter, hitting analysts' consensus estimates of ($0.12). The business had revenue of ($1.00) million for the quarter, compared to the consensus estimate of $0.17 million. Sell-side analysts anticipate that Shattuck Labs will post -0.5 EPS for the current year.

About Shattuck Labs

Shattuck Labs, Inc NASDAQ: STTK is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company's lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.